These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 8996340

  • 21. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP.
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [Abstract] [Full Text] [Related]

  • 24. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
    Yamada Y, Hara I, Kumano M, Furukawa J, Yamanaka K, Kamidono S.
    Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
    [Abstract] [Full Text] [Related]

  • 25. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, Sylvester R, European Organization for Research and Treatment of Cancer Genitourinary Group.
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study.
    Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, Mori K, Kamimura N, Koie T, Yamato T, Suzuki T.
    Urology; 2008 Jun; 71(6):1161-5. PubMed ID: 18279920
    [Abstract] [Full Text] [Related]

  • 33. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
    Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R, CUETO Group (Club Urológico Español De Tratamiento Oncológico).
    Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
    [Abstract] [Full Text] [Related]

  • 34. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 35. Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
    Herr HW, Dalbagni G.
    J Urol; 2003 May; 169(5):1706-8. PubMed ID: 12686813
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical study of bladder cancer: Proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy.
    Satoh A, Hanawa Y, Nakamura S.
    Int J Urol; 2004 Jul; 11(7):476-82. PubMed ID: 15242355
    [Abstract] [Full Text] [Related]

  • 38. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM.
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [Abstract] [Full Text] [Related]

  • 39. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
    Ovesen H, Horn T, Steven K.
    J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.